As
cancer appeared more frequently in patients treated with
simvastatin-
ezetimibe combination therapy in one clinical trial,[11] it had been
hypothesized that NPC1L1 by ezetimibe might be associated with an increased cancer risk.[12] However, a
meta-analysis of ezetimibe
clinical data showed no increase in the risk of cancer from treatment with ezetimibe.[13]
^Savarese G, De Ferrari GM, Rosano GM, Perrone-Filardi P (December 2015). "Safety and efficacy of ezetimibe: A meta-analysis". International Journal of Cardiology. 201: 247–52.
doi:
10.1016/j.ijcard.2015.08.103.
PMID26301648.
Overview of all the structural information available in the
PDB for
UniProt: Q9UHC9 (Human NPC1-like intracellular cholesterol transporter 1) at the
PDBe-KB.
As
cancer appeared more frequently in patients treated with
simvastatin-
ezetimibe combination therapy in one clinical trial,[11] it had been
hypothesized that NPC1L1 by ezetimibe might be associated with an increased cancer risk.[12] However, a
meta-analysis of ezetimibe
clinical data showed no increase in the risk of cancer from treatment with ezetimibe.[13]
^Savarese G, De Ferrari GM, Rosano GM, Perrone-Filardi P (December 2015). "Safety and efficacy of ezetimibe: A meta-analysis". International Journal of Cardiology. 201: 247–52.
doi:
10.1016/j.ijcard.2015.08.103.
PMID26301648.
Overview of all the structural information available in the
PDB for
UniProt: Q9UHC9 (Human NPC1-like intracellular cholesterol transporter 1) at the
PDBe-KB.